Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-CD3 & Anti-CD7 Immunotoxins in Steroid-Resistant Acute GVHD
NCT00640497Phase 2Withdrawn
- Sponsor
- Henogen
- Start
- Jan 2010
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD3 ricin A immunotoxin and anti-CD7 ricin A immunotoxin in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Henogen. Primary endpoint: Acute GVHD response rate at Day 29. Planned start Jan 2010; status: withdrawn.
02
Drugs
anti-CD3 ricin A immunotoxinanti-CD7 ricin A immunotoxin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00640497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640497.